Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.5 USD | +13.64% | +13.64% | -42.75% |
Apr. 05 | Archon Capital Management Engages with Apyx Medical Corporation | CI |
Apr. 01 | Stavros G. Vizirgianakis Engages in Discussions with Apyx Medical Corporation | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-42.75% | 51.97M | C | ||
-2.89% | 185B | C+ | ||
-2.43% | 107B | C | ||
-4.10% | 67.55B | A | ||
+11.10% | 54.6B | B- | ||
+15.86% | 47.42B | B- | ||
+3.86% | 42.24B | B+ | ||
+9.55% | 28.24B | A- | ||
+1.85% | 26.42B | B | ||
+12.40% | 25.66B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- APYX Stock
- Ratings Apyx Medical Corporation